Project: SAFETY and EFFICACY of ESTETROL PULSED TREATMENT:an INNOVATION for MENOPAUSE therapy
| Acronym | SEPTIME (Reference Number: 10069) |
| Duration | 01/03/2016 - 01/03/2018 |
| Project Topic | SEPTIME will develop a sublingual Estetrol (E4) treatment for menopausal symptoms. Oral estrogens (E), the most powerful drugs for climacteric complaints, increase the risk of vascular events and of breast cancer.E4 is a natural fetal human E with limited impact on coagulation and breast. SEPTIME will deliver a sublingual E4 formulation and document its additional endometrial, breast, urogenital and vascular safety / efficacy versus the oral route in preclinical models. |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 4 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 22753 | Mithra Pharmaceuticals sa | Coordinator | Belgium |
| 22754 | University of Liège - Laboratory of Tumor and Development Biology | Partner | Belgium |
| 22755 | INSERM | Partner | France |
| 22756 | UROsphere SAS | Partner | France |